

Are the Apparent Survival Benefits of Hemodiafiltration Due to Changes in Extracorporeal Temperature?

Prof. Bernard Canaud

Montpellier University, School of Medicine, Montpellier-F

& Senior Medical Scientist, Global Medical Office FMC, Bad Homburg-G



Are the Apparent Survival Benefits of Hemodiafiltration Due to Different Thermal Energy Balance?

Prof. Bernard Canaud

Montpellier University, School of Medicine, Montpellier-F

& Senior Medical Scientist, Global Medical Office FMC, Bad Homburg-G




Outline — Are the Apparent Survival Benefits of HDF Due to Different Thermal Balance?

- 1 What are the Evidences?**
 - 2 What is the Main Organ Target of HDF?**
 - 3 Why Hemodiafiltration Acts Differently?**
 - 4 What Role for Thermal Energy Balance?**
 - 5 Any Role for Non-Thermal Factors?**
 - 6 Take home message: HDF has a Cardiac Protecting Effect**
-

Outline — Are the Apparent Survival Benefits of HDF Due to Different Thermal Balance?

- 1 What are the Evidences?**
- 2 What is the Main Organ Target of HDF?
- 3 Why Hemodiafiltration Acts Differently?
- 4 What Role for Thermal Energy Balance?
- 5 Any Role for Non-Thermal Factors?
- 6 Take home message: HDF has a Cardiac Protecting Effect

What is Evidence-Based Medicine ?




Science-Based EBM Applied to Hemodiafiltration

VIRTUAL MEDICINE

REALITY

REAL MEDICINE

HIGHLY SELECTED POPULATION



RANDOMIZED CONTROLLED STUDIES

UNSELECTED POPULATION







POPULATION BASED STUDIES

Primary Outcome HDF vs HD


Outcome is Improved When Right Dosage Is Delivered

Randomized
Controlled Trials



Convective Dose Dependency CV Mortality

Total Ultrafiltered Volume Distribution Per Study




European Pooling Project



HDF European Pooling Project

Four Randomized Clinical Trials

Individual Patient Data
Meta-Analysis



mode	HD	Ol-HDF	Ol-HDF	Ol-HDF
Ol-HDF dose		Lowest	Middle	Highest
Convection volume (l)	NA	18.0 (16.0–18.8)	21.0 (20.2–22.0)	25.7 (24.4–27.4)
Number	1393	433	447	435
Body surface area (m ²)	1.77 (0.22)	1.72 (0.23)	1.77 (0.20)	1.80 (0.20)
BMI post dialysis (kg/m ²)	25.2 (4.6)	24.7 (5.0)	24.9 (4.6)	25.8 (4.8)
Weight (kg)	68.7 (15.4)	66.2 (14.6)	68.9 (13.7)	71.5 (14.5)
Total body water (l)	35.1 (6.5)	34.6 (6.7)	35.3 (6.2)	35.0 (6.2)

Pooled individual patient analysis of four prospective trials compared thirds of delivered convection volume with hemodialysis. Convection volumes were either not standardized or standardized to weight, body mass index, body surface area, and total body water. Data were analyzed by multivariable Cox proportional hazards modeling from 2793 patients.

Effects of Pooled Database on HR

HDF is Associated with a Significant Reduction of Mortality Risk

Individual Patient Data
Meta-Analysis


A Pooled Meta-Analysis of Individual Participant Data* from four randomized controlled trials



Cause	HD			HDF			HR (95% CI) for HDF versus HD
	n	Events	Events/100 PY	n	Events	Events/100 PY	
All-causes	1369	410	12.10	1367	359	10.45	0.86 (0.75; 0.99) ↘14%
Cardiovascular disease	1302	164	4.84	1289	128	3.73	0.77 (0.61; 0.97) ↘23%
Infections	1302	77	2.27	1289	73	2.13	0.94 (0.68; 1.30)
Sudden death	1302	56	1.65	1289	56	1.63	0.99 (0.68; 1.43)

HDF is Associated With Better Outcome with High Volume Convection

Cohort Study
National Registry



The Japanese Society for
Dialysis Therapy

HDF is Associated with Better Outcome at Patient Level and at Facility Level

Cohort Study
National Registry

	All-Cause Mortality ^a	Cardiovascular Mortality ^b	Noncardiovascular Mortality ^b
Patient-level predictor analyses			
Sex-adjusted model, HDF	0.81 (0.74-0.89)	0.71 (0.59-0.86)	0.86 (0.78-0.95)
Fully adjusted model, ^c HDF	0.84 (0.77-0.91)	0.73 (0.61-0.88)	0.89 (0.81-0.97)
Fully adjusted model, ^c HDF exclusive vs never	0.77 (0.67-0.87)	0.66 (0.50-0.86)	0.82 (0.72-0.92)
Facility-level predictor analyses ^d			
Overall population	0.87 (0.77-0.99)	0.72 (0.54-0.96)	0.96 (0.84-1.09)
In-center and satellite facility patients	0.82 (0.72-0.94)	0.68 (0.51-0.93)	0.90 (0.78-1.04)



**French Renal Epidemiology and
Information Network Registry (REIN)**



22,881 were not
treated with HDF

5,526 were treated at
least once with HDF

2,254 exclusively
treated with HDF

HDF is Associated with Better Outcome Over 10 Years Period both in Australia & New Zealand

Cohort Study
National Registry



4,110 were regularly
treated with HDF


22,851 were regularly
treated with HD

Outline — Are the Apparent Survival Benefits of HDF Due to Different Thermal Balance?

- 1 What are the Evidences?
 - 2 What is the Main Organ Target of HDF?
 - 3 Why Hemodiafiltration Acts Differently?
 - 4 What Role for Thermal Energy Balance?
 - 5 Any Role for Non-Thermal Factors?
 - 6 Take home message: HDF has a Cardiac Protecting Effect
-

Intra Dialytic Hypotension is Reduced in HDF

Total incidence of IDH 7.5% 28950 sessions




Italian C/D Study

Italian Multicenter Convective vs Diffusive Study

Intradialytic Morbidity is Reduced in Elderly Patients with HDF


Reduced incidence of hypotensive episodes and cramps



A Cause-Specific Analysis of HD/HDF Shows Cardiac Benefit Exclusively

Annualized CVD mortality per 100 patient-years in the HD and oHDF groups. The numbers in boxes represent fatal CVD


■ unclassified CVD ■ non-cardiac ■ cardiac p=0.01



Outline — Are the Apparent Survival Benefits of HDF Due to Different Thermal Balance?

- 1 What are the Evidences?
 - 2 What is the Main Organ Target of HDF?
 - 3 **Why Hemodiafiltration Acts Differently?**
 - 4 What Role for Thermal Energy Balance?
 - 5 Any Role for Non-Thermal Factors?
 - 6 Take home message: HDF has a Cardiac Protecting Effect
-

Online Hemodiafiltration Has Different Features and Biologic Actions



1 Enhance Solute Clearance (K)
for Middle & Large MW Substances

High-Flux Membrane

$$K = K_{DIFFUSIVE} + K_{CONVECTIVE}$$

High Convective Volume


2 Ultrapurity of Dialysis Fluid

Reduce Inflammation

3 Different Thermal Energy Balance

Higher Thermal Energy Loss

HDF Provides Significantly Higher β_2 M Clearance & Mass Removal




Inflammation, Oxidative Stress, Nutrition and Anemia Markers Are Improved with Ultrapure Dialysate and HDF

Outcome variables	No. studies	No. patients	Mean net change ^a (95% CI)	P-value
Inflammatory markers				
C-reactive protein, mg/L	9	414	−4.38 (−7.47, −1.29)	0.006
Interleukin-6, pg/mL	9	278	−11.61 (−17.74, −5.49)	<0.001
Interleukin-1 receptor antagonist, ng/mL	2	87	−0.06 (−0.17, 0.04)	0.243
Tumor necrosis factor- α , pg/mL	3	50	−5.50 (−12.86, 1.87)	0.144
Oxidative stress markers				
Oxidized LDL cholesterol, U/L	2	166	−14.04 (−21.26, −6.83)	<0.001
Nutritional markers				
Albumin, g/dL	4	176	0.25 (0.02, 0.48)	0.031
Anemia parameters				
Hemoglobin, g/dL	5	206	0.13 (0.00, 0.26)	0.049
Erythropoietin dose, units/week	5	206	−1188 (−2371, −4)	0.049


Outline — Are the Apparent Survival Benefits of HDF Due to Different Thermal Balance?

- 1 What are the Evidences?
 - 2 What is the Main Organ Target?
 - 3 Why Hemodiafiltration Acts Differently?
 - 4 What Role for Thermal Energy Balance?**
 - 5 Any Role for Non-Thermal Factors?
 - 6 Take home message: HDF has a Cardiac Protecting Effect
-

Hemodialysis as Heat Exchanger System




Terminology Used to Define Thermal Balance in HD is Confusing




Thermal Energy Balance in Standard HD Treatment

Mean Predialysis Auricular Temperature is 36.5°C




Prospective Study
75 Stable HD pts
One week x 3 ses.

Standard Dialysate Temperature is Set at 37–37.5°C




Heat Flow Transfer – Instantaneous Energy Transfer Rate



Online HDF has an Additional Component to Heat Flow Transfer Equation

Substitution and Ultrafiltration Flow and Segments



Thermal Energy Balance in HD Patient – Temperature Gradient

Thermal Energy Balance in HD Patient Results Mainly
from Dialysate–Blood Temperature Gradient

Temp. D > B



**Hyperthermic
Dialysis**

**Patient Gain
Thermal Energy
(kJ/ses. or W/ses.)**

Temp. D = B



**Isothermic
Dialysis**

**No Thermal Energy
Gain/Loss
(kJ/ses. or W/ses.)**


Temp. D < B




**Hypothermic
Dialysis**

**Patient Loss
Thermal Energy
(kJ/ses. or W/ses.)**


Hemodynamic Response to Ultrafiltration and Hyperthermic Dialysis




Hemodynamic Response to Ultrafiltration and Hypothermic Dialysis



Hypothermic Dialysis Reduces Incidence of Intra-Dialytic Hypotensive Episodes



Effect of Thermal Balance Regime on Hemodynamic Behavior (BP & HR)



Hemodynamic Response to Thermal Energy Balance in HD/HDF Patients

Exploring Thermal Balance and Volume Effects: Different Design of Studies

Clinical Studies Exploring Effects of Thermal Balance HD vs. HDF

Dialysate-Blood Temperature Setting



Manual Setting

Dialysate-Blood Temperature Gradient

HD **Isothermic**

— **VS.** —

ol-HDF *High UF Volume*

HD **Hyperthermic**
Hypothermic

— **VS.** —

HDF *Low UF Volume*

HDF *Medium UF Volume*

Substitution Fluid is Maintained
at **Room Temperature**



Automated

Thermocontrolled

Blood Temperature Module (BTM)

Isothermic

HD

— **VS.** —

ol-HDF *High UF Volume*



Hemodynamic Response to HD vs. HDF with Hyperthermic HD

Reduction of Intradialytic Hypotension with HDF and Hypothermic HD

Prospective Controlled Studies

Period A

17 Hypotensive prone pts

Period B


25 Stable HD pts

100 Paired consecutive HD/HDF treatments

Control phase 6 weeks – IDH prevalence

Active Intervention:

HD Hyperthermic / Hypothermic
Controlled
Vs. Postdilution HDF



Hemodynamic Response to HDF vs. HD with Hypothermic HD

Significant Reduction of Intradialytic Hypotension Episodes with Hypothermic HD Matching HDF

Prospective Controlled Studies

Period A

17 Hypotensive prone pts

Period B


25 Stable HD pts

100 Paired consecutive HD/HDF
treatments

Control phase 6 weeks – IDH
prevalence

Active Intervention:

HD Hyperthermic / Hypothermic
Controlled
Vs. Postdilution HDF



Hemodynamic Response to HDF vs. HD and Thermal Balance

Comparable Reduction of Intradialytic Hypotension Episodes with Hypothermic HD and HDF


HDF is associated with thermal loss equivalent to hypothermic HD

	Treatment modality	Treatments with hypotension/all treatments (%)	T_{art} 0 min (°C)	ΔT_{av} (°C)	Min BV (%)	ET (W)	Systolic blood pressure (mmHg)	
							Beginning	End
Study A	o-HDF	1/25 (4%)	36.4 ± 0.4	1.2 ± 0.3^c	91.8 ± 3.1	-16.6 ± 4.0^e	144.0 ± 17.9	141.2 ± 17.9
		10/25 ^a (40%)	36.5 ± 0.5	$0.4 \pm 0.4^{c,b}$	94.0 ± 3.2^d	$-5.4 \pm 5.1^{b,e}$	142.1 ± 19.6	124.9 ± 17.5^c
Study B	o-HDF	1/25 (4%)	36.5 ± 0.5	1.2 ± 0.3^c	92.9 ± 4.0	-15.9 ± 1.9^e	144.0 ± 27.3	131.8 ± 25.8
	Temp-HD	1/25 ^f (4%)	36.5 ± 0.3	1.1 ± 0.1^c	93.5 ± 3.8	-16.3 ± 4.2^e	143.2 ± 28.1	135.8 ± 27.8

	Study A		Study B	
	o-HDF	HD	o-HDF	Temp-HD
Mean blood flow (ml/min)	222.7 ± 14.8	214.4 ± 20.3	215.8 ± 17.8	222.4 ± 27.2
Mean ultrafiltration volume (l)	2.6 ± 1.0	2.5 ± 0.9	2.1 ± 0.7	2.2 ± 0.8
Replacement fluid prescribed per treatment (ml/min)	50	—	50	—
Dialysate flow (ml/min)	500	500	500	500
Mean dialysate temperature	36.8 ± 0.4	36.8 ± 0.3	36.9 ± 0.3	35.6 ± 0.4

Intradialytic Hemodynamic HDF vs. HD with Isothermic Conditions

Mean Arterial Pressure Decline in Similar Way




	HD	HDF pre
Ultrafiltration <i>mL</i>	3066 ± 276	2992 ± 256
Relative blood volume%	90 ± 1.9	89 ± 1.1
Total energy transfer <i>kJ</i>	155 ± 42	135 ± 39

Prospective Crossover RC Study

12 HD pts - 4hrs x 3 wk
High Flux HD vs. HDF Predilution High Volume 85±15l/ses.
ISOTHERMIC CONTROLLED CONDITION (BTM)
Intradialytic Hemodynamic Monitoring – US Transsonics


Intradialytic Hemodynamic of HDF vs. HD with Isothermic Conditions

Cardiac Performance Decline Follows Blood Volume Reduction



Intradialytic Hemodynamic HDF vs. HD with Isothermic Conditions

Higher Increase in Total Peripheral Resistance with HDF



Prospective Crossover RC Study
 12 HD pts - 4hrs x 3 wk
 High Flux HD vs. HDF Predilution High Volun
 ISOTHERMIC CONTROLLED CONDITION (BTM)
 Intradialytic Hemodynamic Monitoring - US Transonics

Thermal Balance and Temperature Change in HD vs. HDF

Cooling Effect of online HDF

Prospective Controlled Studies

Period A

17 Hypotensive prone pts

Period B


25 Stable HD pts

100 Paired consecutive HD/HDF treatments

Control phase 6 weeks – IDH prevalence

Active Intervention:

HD Hyperthermic / Hypothermic
Controlled
Vs. Postdilution HDF




Effects of Thermal Balance and Substitution Volume on Hemodynamic during HDF vs. HD

12 HD pats

Same treatment conditions
4hrs x 3wk – Qb 300 QD 500
Dialysate Electrolyte Composition
Dialyzer: Polyamide
Same day & Hours – UFR ...

2 x 2 Factorial Study



	HD 35.5°	HDF 1L/h (6L/ses.)	HD 37.5°	HDF 2.5L/H (10L/ses.)
WL (l/ses.)	2.2 ± 0.6	2.3 ± 0.7	2.4 ± 0.7	2.3 ± 0.8 L
TVUF (l/ses.)	2.2 ± 0.6	8.3 ± 1.7	2.4 ± 0.7	12.3 ± 1.8 L

Hemodynamic Monitoring: AP, MAP, HR...
Energy Transfer Rate – Blood volume control

*HDF substitution fluid bag, room temperature

Thermal Effects on Hemodynamic during HDF & HD

Effect of Amount of Replacement Fluid and Dialysate Temperature

Total ultrafiltration volume is correlated with negative thermal energy balance

Modality	ΔCT (C)	ET (W)	ΔMAP (mmHg)	ΔBV (%)	UF (l/ses.)
HD ^{37.5}	$+0.38 \pm 0.22$	-3.53 ± 6.44	-25.6 ± 13.5	-7.3 ± 5.0	2.2 ± 0.6
HD ^{35.5}	$+0.00 \pm 0.29$	-26.61 ± 5.33	-15.1 ± 13.8	-9.8 ± 4.8	2.3 ± 0.7
HDF ¹	$+0.29 \pm 0.23$	-15.88 ± 6.94	-23.0 ± 14.0	-9.1 ± 6.1	2.4 ± 0.7
HDF ^{2.5}	-0.10 ± 0.40	-25.25 ± 7.91	-19.2 ± 17.7	-9.8 ± 6.5	2.3 ± 0.8

^a Values are mean \pm SD [range]. HD^{37.5} and HD^{35.5} are ultrafiltration combined with hemodialysis at a dialysate temperature of 37.5°C and 35.5°C, respectively; HDF¹ and HDF^{2.5} are postdilution hemodiafiltration with amount of replacement fluid at room temperature of 1 L/h and 2.5 L/h respectively. ET, energy transfer rate in W (watts); ΔCT , change in core temperature *versus* baseline in °C; ΔMAP , is maximum decrease in mean arterial blood pressure in mmHg; ΔBV , change in blood volume *versus* baseline in %.



^b $P < 0.05$; changes *versus* baseline.

^c $P < 0.05$; *versus* HD^{37.5}.

^d $P < 0.05$; *versus* HDF¹.

Intradialytic Hemodynamic under Thermocontrolled Conditions

Imaging by Cardiac MRI – Clinical Setting for in vivo Assessment



Hemodynamic Behavior of HD vs. HDF


No Significant Difference in Isothermic Controlled Conditions

*Fits closely with
intradialytic blood
volume change* →

Substitution volume, l n/a 23.0 ± 2.5
UF rate, ml/kg per h 3.8 ± 2.9 4.4 ± 2.5
UF volume, L 1.1 ± 0.7 1.3 ± 0.6

Prospective Crossover RC Study

12 HD patients - High Flux HD vs. HDF
ISOTHERMIC CONTROLLED BTM
Intradialytic Hemodynamic Assessment
Intradialytic Cardiac MRI



Outline — Are the Apparent Survival Benefits of HDF Due to Different Thermal Balance?


- 1 What are the Evidences?
 - 2 What is the Main Organ Target?
 - 3 Why Hemodiafiltration Acts Differently?
 - 4 What Role for Thermal Energy Balance?
 - 5 Any Role for Non-Thermal Factors?
 - 6 Take home message: HDF has a Cardiac Protecting Effect
-

Non-Thermal Factors Contributing to Hemodynamic Response

- Inflammation – Oxidative Stress
 - Endothelial Dysfunction
 - Pulse Wave Velocity
 - Sympathetic Nerve Activity
 - Cardiac Arrhythmogenic Activity
-

Time Behavior of CRP in Patients Treated with HD and HDF

CRP Remains stable in HDF and Increases in HD



CONTRAST

CONvective TRANsport STudy

Effects of HD/HDF on Endothelial Dysfunction

Correlate with Markers of Oxidative Stress, Inflammation & NO Pathway



Endothelial dysfunction is reduced with HDF

	Baseline		Change after 4 months		P value
	HD	HDF	HD	HDF	
Oxidative stress					
TBARs (μmol/L) Median (IQR)	0.24 (0.19–0.32)	0.22 (0.16–0.45)	0.02 (–0.1 to 0.2)	–3 (–0.2 to 0.2)	0.34
ROS (μmol/L) Median (IQR)	34.7 (29.5–50.0)	38.3 (30.0–49.5)	–3 (–11 to 2)	–3 (–13 to 19)	0.34
TAS (mmol/L) Median (IQR)	1.55 ± 0.22	1.58 ± 0.26	–0.16 ± 0.29	–0.18 ± 0.40	0.99
Inflammation					
hs-CRP (mg/L)	4.4 (1.8–16)	4.7 (2.1–13.5)	1 (–2 to 4)	–1 (–6 to 3)	0.40
TNFα mRNA to 18S rRNA ratio Median (IQR)	0.61 (0.56–0.88)	0.51 (0.42–1.12)	0.37 (0.30 to 1.02)	–0.16 (–0.24 to 0.10)	<0.001
NO pathway					
PKCβ ₂ mRNA to 18S rRNA ratio Median (IQR)	0.59 (0.56–0.70)	0.48 (0.36–0.59)	0.12 (0.03 to 0.31)	–0.07 (–0.28 to 0.11)	<0.001
P85β mRNA to 18S rRNA ratio Median (IQR)	0.80 (0.58–1.12)	0.77 (0.60–1.00)	–0.04 (–0.27 to –0.0)	–0.11 (–0.40 to 0.34)	0.48


Prospective RC Trial

42 prevalent HD patients
High vol. HDF vs. HD – 4Mo FU
Hemodynamic monitoring
Inflammation – Oxidative Stress
Endothelial function monitoring

Effects of HD/HDF on Endothelial Dysfunction

Flow Mediated Dilatation

Flow mediated dilatation is improved with HDF




Prospective RC Trial
42 prevalent HD patients
High vol. HDF vs. HD - 4Mo FU
Hemodynamic monitoring
Inflammation - Oxidative Stress
Endothelial function monitoring

Effects of HD/HDF on Endothelial Dysfunction

Carotid Distensibility

Carotid distensibility is improved with HDF




Prospective RC Trial
42 prevalent HD patients
High vol. HDF vs. HD - 4Mo FU
Hemodynamic monitoring
Inflammation - Oxidative Stress
Endothelial function monitoring

Effects of HD/HDF (HFR) on Oxidative Stress

HDF Reduced Both Mononuclear Cell mRNA Expression and Protein Level of p22phox

p22phox* expression is reduced with HDF


*subunit of NADPH oxidase generating superoxide anion ($O_2^{\cdot -}$)



Effects of HD/HDF (HFR) on Inflammatory Cytokines

HDF Reduced both Mononuclear Cell of RNA and Protein Level of Plasminogen Activator Inhibitor (PAI-1)

PAI-1, Plasminogen Activator Inhibitor 1* expression is reduced
Marker of oxidative stress-related response to inflammatory cytokines





Effects of HD/HDF (HFR) on Inflammatory Cytokines

HDF Increased the Protein Expression of Heme Oxygenase (HO-1)



HO-1: Antioxidant, anti-inflammatory, anti-proliferative & oxidized LDL



Effects of HDF vs. HD on Inflammation, OS and ED in ESKD Infants

3H Study Pediatric


HDF, Heart & Height Study

Prospective interventional
controlled multicentric study

Four Months FU

Effects of HDF vs HD

- Inflammation, Oxidative Stress, Endothelial Dysfunction
- CV & Height Outcomes



Effects of HDF vs. HD on Oxidative Stress

Markers of Oxidative Stress Are Significantly Reduced in HDF

▶ Oxidative stress is reduced and total antioxidant capacity improved in HDF


3H Study Pediatric

HDF, Heart & Height Study

Prospective interventional
controlled multicentric study
Four Months FU

Effects of HDF vs HD

- Inflammation, Oxidative Stress, Endothelial Dysfunction
- CV & Height Outcomes



Effects of HDF vs. HD on Inflammation

Inflammation Markers and B2M Are Reduced with HDF

Inflammation is reduced with HDF


3H Study Pediatric

HDF, Heart & Height Study

Prospective interventional
controlled multicentric study
Four Months FU

Effects of HDF vs HD

- Inflammation, Oxidative Stress, Endothelial Dysfunction
- CV & Height Outcomes



Effects of HDF vs. HD on Endothelial Dysfunction

Endothelial Function is Improved with HDF



ADMA concentrations are reduced in HDF

3H Study Pediatric


HDF, Heart & Height Study

Prospective interventional
controlled multicentric study

Four Months FU

Effects of HDF vs HD

- Inflammation, Oxidative Stress, Endothelial Dysfunction
- CV & Height Outcomes



Effect of HDF vs. HD on Vascular Stiffness

Aortic Pulse Wave Velocity

Multicenter Prospective Parallel Comparative Study


289 prevalent HD patients: HD 69; 78 HD-HDF; 142 HDF
6 months Follow-Up - Hemodynamic monitoring - CV Event
Blood Pressure - ECG - EchoCG -Pulse Wave Velocity

	HD	HD to HDF	HDF
Patients, n	69	78	142
Age, years	64.2±15.2	64.1±16.5	67.0±19.7
Males, %	65.2	59.0	62.6
Diabetics, %	44.9	56.4	44.4
Weight, kg	72.5±16.6	71.9±17.5	70.5±16.3
Body mass index	26.1±5.8	25.8±5.2	25.7±5.2
Dialysis vintage, months	24 (7–52)	28.5 (14–50)	39 (21–75)*
Dialysis session, h	3.92±0.36	3.93±0.42	3.99±0.37
Hypertension, %	72.2	66.7	85.9
IHD, %	20.3	32.1	31.7
PVD, %	14.5	14.1	23.9
CVD, %	8.7	12.8	19.7
Current smokers, %	14.5	13.7	3.5
Ex-smokers, %	29.0	27.5	24.6
ACEI/ARB, %	33.3	33.3	31.5
CCB, %	24.6	15.4	22.5
BB, %	42.0	12.8*	19.7*

Effect of HDF vs. HD on Vascular Stiffness

Aortic Pulse Wave Velocity

▶ Aortic PWV is stabilized with HDF



PWV: aortic pulse wave velocity


Multicenter Prospective Parallel Comparative Study
289 prevalent HD patients: HD 69; 78 HD-HDF; 142 HDF
6 months Follow-Up - Hemodynamic monitoring - CV Event
Blood Pressure - ECG - EchoCG - Pulse Wave Velocity

Effect of HDF vs. HD on Diastolic Coronary Refilling Capacity

Diastolic Relaxation Area

Multicenter Prospective Parallel Comparative Study


289 prevalent HD patients: HD 69; 78 HD-HDF; 142 HDF
6 months Follow-Up - Hemodynamic monitoring - CV Event
Blood Pressure - ECG - EchoCG - Pulse Wave Velocity



DRA: Diastolic relaxation area
a measure of diastolic refilling of the left coronary artery

Effects of HDF vs. HD on Arterial Stiffness

Brachial Pulse Wave Velocity



Prospective RCT Study


HDF(13) vs. Conv. HD(9)- 1 year FU

Surrogate markers: EchoCG-baPWV-IMT

Effects of HD vs. HDF on Autonomic Nervous System Dysfunction

Prospective RC Study


40 HD pts - 20HD vs.20 HDF
24hrs Holter ECG monitoring
Heart Rate Variability (HRV)
Time & frequency domain measures



Effects of HD/HDF on Autonomic Dysfunction

Heart Rate Variability (HRV) is Reduced with HDF

Frequencies domain measures (VLF, HF & LF) increase significantly with HDF, translating an improvement in autonomic nervous system dysfunction



HRV, Heart Rate Variability
VLF, Very Low Frequency Domain
HF, high Frequency Domain
LF, Low Frequency Domain


Effects of HD/HDF on Intradialytic Cardiac Arrhythmogenicity

Changes In T Peak-end Interval (Tpe)



HDF is associated with a reduced Tpe value meaning less arrhythmic risk


Prospective Randomized Cross-sectional Study
30 HD pats - HD vs. HDF 3 Mo
4h x3 wk - Cardiac assessment
ECG Monitoring & precise analysis: rhythm
EchoCG - Doppler : Structure & Function



Outline — Are the Apparent Survival Benefits of HDF Due to Different Thermal Balance?


- 1 What are the Evidences?
- 2 What is the Main Organ Target?
- 3 Why Hemodiafiltration Acts Differently?
- 4 What Role for Thermal Energy Balance?
- 5 Any Role for Non-Thermal Factors?
- 6 **Take home message: HDF has a Cardiac Protecting Effect**

HDF is Associated with Negative Thermal Balance and Intradialytic Hemodynamic Benefits



Beyond Thermal Balance HDF Has Additional CV Benefits

HEMODIAFILTRATION



Crush Injury and Beyond: Disaster Nephrology

Norbert Lameire, MD, PhD
Emeritus Professor of Medicine
University Hospital
Ghent, Belgium

With sincere thanks to Raymond Vanholder and Mehmet S Sever

Virtual Annual Dialysis Conference Meeting
March 7, 2021

Disaster-WHO Definition

“an act of nature of such magnitude as to create a catastrophic situation in which the day-to-day patterns of life are suddenly disrupted and people are plunged into helplessness and suffering and as a result need food, clothing, shelter, medical and nursing care and other necessities of life, and protection against unfavorable environmental factors and conditions.”

**Sudden calamities
producing extensive
damage, loss and distress**

➔ **Natural**

- ➔ Earthquakes
- ➔ Landslides
- ➔ Avalanches
- ➔ Hurricanes
- ➔ Tornadoes

➔ **Man-made**

- ➔ War
- ➔ Mining
- ➔ Tunnel collapse
- ➔ Terrorism, torture



315
Disaster Events

348*

*2008-2017 Yearly Average

11,804
Deaths

67,572*

68.5 million
Total Affected

198.8 million*

US\$ 131.7 Billion
Damages

\$166.7 Billion*


Number of Disaster Events By Continent

A



B


Share by Disaster Type in 2018



Definitions

- *Rhabdomyolysis*: Damage to striated muscle resulting in the systemic release of intramuscular components
- *Crush injury*: Direct injury by collapsing material and debris causing muscle swelling and/or neurological disturbances in the affected parts of the body
- *Crush syndrome*: Crush injury combined with systemic manifestations, including AKI, sepsis, ARDS, DIC, bleeding, hypovolemic shock, cardiac failure, arrhythmias, electrolyte disturbances

Pathogenesis of rhabdomyolysis



Cote et al, J of Anesthesia
(2020) 34:585–598

A. Clinical significance of the CPK level

Diagnosis	CK level	Clinical Significance	Treatment Needed
Normal CK level	~40-200 U/L		
Mild rhabdomyolysis	1,000-5,000 U/L	Low risk for kidney injury	Possible Depends on context
Moderate rhabdomyolysis	5,000-15,000 U/L	Increased risk of renal injury	Yes
Severe rhabdomyolysis	>15,000 U/L	Increased risk of dialysis	Yes

Variable	Points
Age, years	
≤50	0
51-70	1.5
71-80	2.5
>80	3
Sex	
Male	0
Female	1
Initial Creatinine	
<1.4 mg/dL (<124 μmol/L)	0
1.4-2.2 mg/dL (124-195 μmol/L)	1.5
>2.2 mg/dL (>195 μmol/L)	3
Initial Calcium <7.5 mg/dL (1.88 mmol/L)	No 0
Initial CK > 40000 U/L	Yes 2
	No 0
	Yes 2
Rhabdo secondary to seizures, syncope, exercise, statins or myositis	Yes 0
	No 3
Initial Phosphate	
<4.0 mg/dL (<1.0 mmol/L)	0
<4.0-5.4 mg/dL (1.0-1.4 mmol/L)	1.5
>5.4 mg/dL (>1.4 mmol/L)	3
Initial Bicarbonate <19 mEq/L (19 mmol/L)	No 0
	Yes 2

B. The McMahon Risk Score of RRT and/or mortality in Rhabdomyolysis


A low risk score predicted a favorable outcome: a score of < 5 identified patients with a 3% risk of the **primary outcome**, while a score of > 10 was associated with a risk of 59.2%.

McMahon et al, JAMA Intern Med.
2013;173:1821-1828

The Compartment Syndrome



- ➔ **Compartment: space restricted by the rigid fasciae surrounding the muscles**



Compartment syndrome

- ➔ **increased pressure in the compartments due to traumatic tissue swelling**



Disrupts perfusion / hinders muscle function

FASCIOTOMIES in the Marmara E.

**397 fasciotomies
in 323 patients**

Sepsis: Fasc. (+): 25%
Fasc. (-): 13%

Mortality Sepsis (+): 27%
Sepsis (-): 12%

Sever et al. NDT 2002

**Fasciotomies ⇒
objective criteria**

Better et al. KI 2003;63:1155-1157



FOLLOWING DISASTERS:

CRUSH SYNDROME



the second most frequent cause of death (following direct trauma) Ukai, Ren Fail, 1997




RENAL DISASTER

Primary importance

Secondary importance

Tertiary importance



Crush Syndrome History



First described in the German literature in victims of Messina earthquake of 1909

WW I Germans noted traumatic rhabdomyolysis

A. Hackard “vasomotorische nephrose”

Minami in 1924 linked rhabdomyolysis and renal failure






Abb. 3. Schnitt aus Nierenrinde (Fall 1159). Tod nach Verschüttung am 7. Tag. Hämalaunfärbung. Leitz, Oc. 1, Obj. 6, Tub. 155. *pgr* = Pigmentgranula in dichter Lagerung innerhalb von Tubuli contorti; *pb* = Pigmentstreifen und -bänder; *e* = Epithelien der Tubuli contorti; *bl* = geschrumpfte rote Blutkörperchen in Blutcapillaren.

Virchows Archiv für
pathologische Anatomie
und Physiologie und für
klinische Medizin, Ueber
Nierenveränderungen
nach Verschüttung,
Seigo Minami (1923)
245: 247-267.

The London Blitz: September 1940- More than one million houses were destroyed or damaged and more than 40000 civilians died





Prof. Eric Bywaters
1910-2003

BRITISH MEDICAL JOURNAL

LONDON SATURDAY MARCH 22 1941

CRUSH INJURIES WITH IMPAIRMENT OF RENAL FUNCTION

BY

E. G. L. BYWATERS, M.B., B.S., M.R.C.P.

Beit Memorial Fellow


AND

D. BEALL, Ph.D. Toronto

(From the Departments of Medicine and Pathology, British Postgraduate Medical School)

[WITH SPECIAL PLATE]

- ➔ Four crushed cases
- ➔ Three oliguric
- ➔ Dark brownish urine color
- ➔ All died
- ➔ Autopsies were performed



1988: The Armenian Earthquake

- Death toll: 25,000 ?
- Crush cases: 600 ?
- Many crush pts. died due to lack of dialysis

No organized international support structure was available

Eknoyan G. Ren Fail 1992; 14: 241

Need for preplanned logistic organisation



RENAL DISASTER RELIEF TASK FORCE

Supplementation of MEDICAL MATERIAL and PERSONNEL

International relief \neq functional help

- **Guatemalan e.1976 \Rightarrow 90% drugs useless (unsorted)** Seaman, Injury, 1990
- **Armenian e.1978 \Rightarrow 70% useless (expired or damaged)** Auiter, Lancet, 1990

No organized international support structure was available

Eknoyan G. Ren Fail 1992; 14: 241

International personnel support \Rightarrow useful or harmful

Local / Global integrated responses are mandatory !



RENAL DISASTER RELIEF TASK FORCE

INVITED CONTRIBUTION

International dialysis aid in earthquakes and other disasters¹

KIM SOLEZ, DAVID BIHARI, ALLAN J. COLLINS, GARABED EKNOYAN, HASKEL ELIAHOU,
V.D. FEDOROV, CARL KJELLSTRAND, NORBERT LAMEIRE, JOSEPH LETTERI,
ALLEN R. NISSENSON, ERIC K. NOJI,² J.P. WAUTERS,
and YASUHIRO YAMAMOTO

University of Alberta Hospitals, 5B4.02 W.C. Mackenzie Health Sciences Centre, Edmonton, Alberta, Canada; Guy's Hospital, London, England, United Kingdom; Hennepin County Medical Center, University of Minnesota, Minneapolis, Minnesota, and Baylor College of Medicine, Houston, Texas, USA; Chaim Sheba Medical Center, Tel-Aviv University, Tel-Hashomer, Israel; A.V. Vishroosby Surgical Institute, Moscow, Russia; University of Alberta Hospitals, Edmonton, Canada; University Hospital, Ghent, Belgium; Long Island Kidney Institute, Freeport, New York, UCLA School of Medicine, Los Angeles, California, and The Johns Hopkins Hospital, Baltimore, Maryland, USA; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Nippon Medical School, Tokyo, Japan, and for the ISN Commission on Acute Renal Failure

ISN Renal Disaster Relief Task Forces

- **Creation of a Latin-American Disaster Relief Task Force- MSF, The Latin-American Societies of Nephrology, dialysis industries. Coordinator: Dr. A. Hurtado**
- **Creation of a North-American Task Force –MSF Canada, ASN, ISN. Coordinators: Drs.Peter Blake (Canada), Tom Parker (USA)**
- **Creation of a European Task Force, ISN, MSF, dialysis industries. Coordinator: Dr Norbert Lameire (Gent, Belgium)**
- **Later added ASN Disaster Relief Task Force : Coordinator, Dr D. Portilla**
- **Later added: South East Asia Task Force: Coordinators:Drs David Harris (Australia), Vivek Jha, (India)**


Conditions and advantages of cooperation with Médecins sans Frontières

- **MSF has over the years accumulated an enormous experience in disaster relief all over the world.**
- **MSF has permanent links and access to the Ministry of Foreign Affairs for quickly obtaining visa, solving a number of diplomatic and logistic problems. The organisation is known world-wide for its strict political neutrality and has therefore access to countries where other organisations could not have access (Nobel Prize for Peace 1999).**
- **They also dispose of very sophisticated communication systems**
- **In the disaster area, the overall organisational and medical command is in the hands of MSF.**
- **MSF financially supports travel, accomodation, and insurance of all volunteers**
- **MSF finances all medical and dialysis equipment needed for the acute dialysis of the victims**

“No! It’s not cocaine, it’s kayexalate! I am on a humanitarian mission...!”



The Global and Local Organisation & Coordination of the RDRTF



MEDICAL INTERVENTIONS AT THE DISASTER FIELD (FOR PROPHYLAXIS OF CRUSH SYNDROME)


**EARLY FLUID
ADMINISTRATION
IS OF VITAL
IMPORTANCE !**



Better and Stein, NEJM, 1990


Vanholder et al, Kidney Int, 2000

Fluid management in crush victims of mass disasters



Evolution of AKI population Marmara earthquake

(n: 639, overall mortality: 15,2%)



Interventions of the RDRTF

- Iran, March, 1997: Material support
- Macedonia, May, 1999: Evacuation chronic patients
- Macedonia/Kosova, July, 1999: Material support
- Turkey, August, 1999: Major intervention
- Kosova, February, 2000: Educational support
- India, January, 2001: Assessment
- Turkey, May, 2003: Material support
- Algeria, May, 2003: Assessment
- Iran, December, 2003: Major intervention
- Luisiana, August, 2005: Advisory role
- Pakistan, October 2005: Major intervention
- Indonesia, May, 2006: Assessment
- Lebanon, July, 2006: Material support
- Peru, August, 2007: Scouting
- China, May 2008, Major intervention
- Italy, April 2009, Advice
- Indonesia, September 2009, Assessment
- Haiti, January 2010, Major intervention
- Chile, February 2010, Advice
- Turkey, March 2010, Advice
- New Zealand 2010 & 2011, Advice
- Ivory coast, 2012, Material support
- Lybia, May 2012, Material support
- Phillipines, December 2013, Material support
- Syria, March-April 2014, Material support
- Nepal, April-May, 2015, Material support



ISSN 0931-0509 (Print) ISSN 1460-2385 (Online)
Volume 27 Supplement 1 April 2012

ndt

NEPHROLOGY DIALYSIS TRANSPLANTATION

Basic and clinical renal science

RECOMMENDATIONS FOR THE MANAGEMENT OF CRUSH VICTIMS IN MASS DISASTERS



Workgroup Co-Chairs: Mehmet Sukru Sever and Raymond Vanholder


Downloaded from <http://ndt.oxfordjournals.org/> at Universitat Externado de Colombia on May 10, 2013

Lessons learned over the years of activity of the RDRTF 1998-2015

- *Nephrological impact of disasters*
 - Crush injury and AKI, pathogenesis, prevention by resuscitation, monitoring and dialysis
 - Acute compartment syndrome
- *Management of chronic dialysis and transplant patients in disaster area*
 - Advance planning
 - Post disaster response: logistics, communications, and supplies
 - Disengagement and debriefing
- *Psychological and mental support of intervention team*



Complex interaction between disasters and HD delivery



Achievements and reflections on the future

- There are some NEW **OPPORTUNITIES** for the RDRTF:
- start up of ISN regional chapters might help and assist in to providing local anchoring of RDRTF
- cooperation with industrial partners might expand both logistical and organisational support for RDRTF
- some nephrology societies (eg French) willing to be more involved and creating their own disaster preparedness renal group
- gradually most regions in the world provide some degree of chronic renal support, providing the necessary and indispensable background to the work of RDRTF.
- There are some **THREATS** for the RDRTF:
- The headquarters are localized in only one single center (Renal division of UH Ghent requiring complex organizational activities, necessitating full-time involvement of one medical coordinator and at least one secretarial assistant.
- In addition, keeping the program and volunteers up-to-date is cumbersome because of unpredictability of interventions
- escalating number of unsafe and war struck areas on a global level
- growing number of regions where dialysis is provided for the happy few, but not for all, creating ethical problems when bringing in acute dialysis opportunities during a short lived window.

Crush Injury and Beyond: Disaster Nephrology

Norbert Lameire, MD, PhD
Emeritus Professor of Medicine
University Hospital
Ghent, Belgium

With sincere thanks to Raymond Vanholder and Mehmet S Sever

Virtual Annual Dialysis Conference Meeting
March 7, 2021

*Thou shalt be visited by the Lord of hosts with thunder,
and with earthquakes and great noise, with storm and
tempest, and the flame of devouring fire.*

Isaiah 29:6

Disaster

**Sudden calamities
producing extensive
damage, loss and distress**

➤ Natural

- Earthquakes
- Landslides
- Avalanches
- Hurricanes
- Tornadoes

➤ Man-made

- War
- Mining
- Tunnel collapse
- Terrorism, torture



315
Disaster Events

348*

*2008-2017 Yearly Average

11,804
Deaths

67,572*

68.5 million
Total Affected

198.8 million*

US\$ 131.7 Billion
Damages

\$166.7 Billion*

Number of Disaster Events By Continent




Figure 1. Global number of climate-related and geophysical disaster events by continent recorded in the International Disaster Database (EM-DAT) in 2018 and compared with the yearly average between 2008 and 2017.⁷

Share by Disaster Type in 2018





Figure 2. Illustration of the percentage of each disaster type registered in 2018.⁷ Abbreviation: Temp, temperature.

Number of deaths by disaster type: 2019
compared to 2009-2018 annual average

45,212
2009 to 2018


11,755
in 2019



Definitions

- *Rhabdomyolysis*: Damage to striated muscle resulting in the systemic release of intramuscular components
- *Crush injury*: Direct injury by collapsing material and debris causing muscle swelling and/or neurological disturbances in the affected parts of the body
- *Crush syndrome*: Crush injury combined with systemic manifestations, including AKI, sepsis, ARDS, DIC, bleeding, hypovolemic shock, cardiac failure, arrhythmias, electrolyte disturbances

Pathophysiology of rhabdomyolysis induced by pressure on muscle cells



COMPARTMENT SYNDROME


- ➔ **Compartment: space restricted by the rigid fasciae surrounding the muscles**

Compartment syndrome

- ➔ **increased pressure in the compartments due to traumatic tissue swelling**



Disrupts perfusion / hinders muscle function



FASCIOTOMIES in the Marmara E.

**397 fasciotomies
in 323 patients**

Sepsis: Fasc. (+): 25%
Fasc. (-): 13%

Mortality Sepsis (+): 27%
Sepsis (-): 12%

Sever et al. NDT 2002

**Fasciotomies ⇒
objective criteria**

Better et al. KI 2003;63:1155-1157



FOLLOWING DISASTERS:

CRUSH SYNDROME



the second most frequent cause of death (following direct trauma) Ukai, Ren Fail, 1997




RENAL DISASTER


Primary importance

Secondary importance


Tertiary importance



Oxidative stress and inflammasome activation in human rhabdomyolysis-induced AKI



Complement activation is a crucial driver of AKI in rhabdomyolysis



Boudanapay I et al, Kidney Int 2020 Oct 30;S0085-2538(20)31244-8.

doi: 10.1016/j.kint.2020.09.033. Online ahead of print.

Crush Syndrome History



First described in German literature in victims of Messina earthquake of 1909

WW I Germans noted traumatic rhabdomyolysis

A. Hackard “vasomotorische nephrose”

Minami in 1924 linked rhabdomyolysis and renal failure






Abb. 3. Schnitt aus Nierenrinde (Fall 1159). Tod nach Verschüttung am 7. Tag. Hämalaunfärbung. Leitz, Oc. 1, Obj. 6, Tub. 155. *pgr* = Pigmentgranula in dichter Lagerung innerhalb von Tubuli contorti; *pb* = Pigmentstreifen und -bänder; *e* = Epithelien der Tubuli contorti; *bl* = geschrumpfte rote Blutkörperchen in Blutcapillaren.

Virchows Archiv für
pathologische Anatomie
und Physiologie und für
klinische Medizin, Ueber
Nierenveränderungen
nach Verschüttung,
Seigo Minami (1923)
245: 247-267.

The London Blitz: September 1940- More than one million houses were destroyed or damaged and more than 40000 civilians died





Prof. Eric Bywaters
1910-2003

BRITISH MEDICAL JOURNAL

LONDON SATURDAY MARCH 22 1941

CRUSH INJURIES WITH IMPAIRMENT OF RENAL FUNCTION

BY

E. G. L. BYWATERS, M.B., B.S., M.R.C.P.

Beit Memorial Fellow


AND


D. BEALL, Ph.D. Toronto

(From the Departments of Medicine and Pathology, British Postgraduate Medical School)

[WITH SPECIAL PLATE]

- ➔ Four crushed cases
- ➔ Three oliguric
- ➔ Dark brownish urine color
- ➔ All died
- ➔ Autopsies were performed






**Kidney of patient who died of uraemia
nine days after release;
gross swelling (weight 192 g)
and pigmented casts**

Bywaters EGJ. BMJ 1990;301:1412-1415

and hot bottles were applied to the loins. Despite these measures, directed towards restarting urine flow, the patient, whose blood pressure was maintained at 130/70, suddenly collapsed at 12:13 p.m. on the eighth day and died in three minutes. A systolic murmur at the



December 7th, 1988; Richter 6.8
20,-40,000 deaths?
600 crush patients?,



Timeline foreign dialysis help in Armenian earthquake

Wednesday December 7th, 1988-6.8 Richter scale

7/12	8/12	9/12	10/12	11/12	12/12	13/12	14/12
Quake	Gorbachov UN speech NY		Visit disaster area Gorbachev	Opening ASN, Request for dialysis help- Arrival German team		British team assembled equipment	Arrival British team Yerevan

Based on Richards, Tattersall, et al, Br Med J 1989;298:443-445

1988: The Armenian Earthquake

- Death toll: 25,000 ?
- Crush cases: 600 ?
- Many crush pts. died due to lack of dialysis

No organized international support structure was available

Eknoyan G. Ren Fail 1992; 14: 241

Need for preplanned logistic organisation



RENAL DISASTER RELIEF TASK FORCE

Supplementation of MEDICAL MATERIAL and PERSONNEL

International relief \neq functional help

- Guatemalan e.1976 \Rightarrow 90% drugs useless (unsorted) Seaman, Injury, 1990
- Armenian e.1978 \Rightarrow 70% useless (expired or damaged) Auiter, Lancet, 1990

No organized international support structure was available

Eknoyan G. Ren Fail 1992; 14: 241

International personnel support \Rightarrow useful or harmful

Local / Global integrated responses are mandatory !



RENAL DISASTER RELIEF TASK FORCE

INVITED CONTRIBUTION

International dialysis aid in earthquakes and other disasters¹

KIM SOLEZ, DAVID BIHARI, ALLAN J. COLLINS, GARABED EKNOYAN, HASKEL ELIAHOU,
V.D. FEDOROV, CARL KJELLSTRAND, NORBERT LAMEIRE, JOSEPH LETTERI,
ALLEN R. NISSENSON, ERIC K. NOJI,² J.P. WAUTERS,
and YASUHIRO YAMAMOTO

University of Alberta Hospitals, 5B4.02 W.C. Mackenzie Health Sciences Centre, Edmonton, Alberta, Canada; Guy's Hospital, London, England, United Kingdom; Hennepin County Medical Center, University of Minnesota, Minneapolis, Minnesota, and Baylor College of Medicine, Houston, Texas, USA; Chaim Sheba Medical Center, Tel-Aviv University, Tel-Hashomer, Israel; A.V. Vishroosby Surgical Institute, Moscow, Russia; University of Alberta Hospitals, Edmonton, Canada; University Hospital, Ghent, Belgium; Long Island Kidney Institute, Freeport, New York, UCLA School of Medicine, Los Angeles, California, and The Johns Hopkins Hospital, Baltimore, Maryland, USA; Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Nippon Medical School, Tokyo, Japan, and for the ISN Commission on Acute Renal Failure

ISN Renal Disaster Relief Task Forces

- **Creation of a Latin-American Disaster Relief Task Force- MSF, The Latin-American Societies of Nephrology, dialysis industries. Coordinator: Dr. A. Hurtado**
- **Creation of a North-American Task Force –MSF Canada, ASN, ISN. Coordinators: Drs.Peter Blake (Canada), Tom Parker (USA)**
- **Creation of a European Task Force, ISN, MSF, dialysis industries. Coordinator: Dr Norbert Lameire (Gent, Belgium)**
- **Recently added ASN Disaster Relief Task Force : Coordinator, Dr D. Portilla**
- **Recently added: South East Asia Task Force: Coordinators:Drs David Harris (Australia), Vivek Jha, (India)**


Role of MSF

- **MSF has over the years accumulated an enormous experience in disaster relief all over the world.**
- **MSF has permanent links and access to the Ministry of Foreign Affairs for quickly obtaining visa, solving a number of diplomatic and logistic problems. The organisation is known world-wide for its strict political neutrality and has therefore access to countries where other organisations could not have access (Nobel Prize for Peace 1999).**
- **They also dispose of very sophisticated communication systems**

Conditions and advantages of cooperation with MSF

- **MSF wants to remain an independent partner and does not want any interference in its own organization.**
- **In the disaster area, the overall organisational and medical command is in the hands of MSF.**
- **MSF insisted on a participation of the Task Force, already in the first hours after the disaster.**
- **MSF financially supports travel, accomodation, and insurance of all volunteers**
- **MSF finances all medical and dialysis equipment needed for the acute dialysis of the victims**

GLOBAL COORDINATION (A)



LOCAL COORDINATION (B)



MEDICAL INTERVENTIONS AT THE DISASTER FIELD (FOR PROPHYLAXIS OF CRUSH SYNDROME)


**EARLY FLUID
ADMINISTRATION
IS OF VITAL
IMPORTANCE !**



Better and Stein, NEJM, 1990


Vanholder et al, Kidney Int, 2000

Fluid management in crush victims of mass disasters



Evolution of AKI population Marmara earthquake

(n: 639, overall mortality: 15,2%)





ISSN 0931-0509 (Print) ISSN 1460-2385 (Online)
Volume 27 Supplement 1 April 2012

ndt

NEPHROLOGY DIALYSIS TRANSPLANTATION

Basic and clinical renal science

RECOMMENDATIONS FOR THE MANAGEMENT OF CRUSH VICTIMS IN MASS DISASTERS



Workgroup Co-Chairs: Mehmet Sukru Sever and Raymond Vanholder

Downloaded from <http://ndt.oxfordjournals.org/> at Universitat Externado de Colombia on May 10, 2013

Interventions of the RDRTF


- Iran, March, 1997: Material support
- Macedonia, May, 1999: Evacuation chronic patients
- Macedonia/Kosova, July, 1999: Material support
- Turkey, August, 1999: Major intervention
- Kosova, February, 2000: Educational support
- India, January, 2001: Assessment
- Turkey, May, 2003: Material support
- Algeria, May, 2003: Assessment
- Iran, December, 2003: Major intervention
- Luisiana, August, 2005: Advisory role
- Pakistan, October 2005: Major intervention
- Indonesia, May, 2006: Assessment
- Lebanon, July, 2006: Material support
- Peru, August, 2007: Scouting
- China, May 2008, Major intervention
- Italy, April 2009, Advice
- Indonesia, September 2009, Assessment
- Haiti, January 2010, Major intervention
- Chile, February 2010, Advice
- Turkey, March 2010, Advice
- New Zealand 2010 & 2011, Advice
- Ivory coast, 2012, Material support
- Lybia, May 2012, Material support
- Phillipines, December 2013, Material support
- Syria, March-April 2014, Material support
- Nepal, April-May, 2015, Material support

Lessons learned over the years of activity of the RDRTF 1998-2015

- *Nephrological impact of disasters*
 - Crush injury and AKI, pathogenesis, prevention by resuscitation, monitoring and dialysis
 - Acute compartment syndrome
- *Management of chronic dialysis and transplant patients in disaster area*
 - Advance planning
 - Post disaster response: logistics, communications, and supplies
 - Disengagement and debriefing
- *Psychological and mental support of intervention team*




Complex interaction between disasters and HD delivery



“No! It’s not cocaine, it’s kayexalate! I am on a humanitarian mission...!”



Role of burnout in health care provision after mass disasters



Achievements and reflections on the future

- There are some **OPPORTUNITIES** for the RDRTF:
- start up of ISN regional chapters might help and assist to provide local anchoring of RDRTF
- cooperation with industrial partners might expand both logistical and organisational support for RDRTF
- some nephrology societies (eg French) willing to be more involved and creating their own disaster preparedness renal group
- gradually most regions in the world provide some degree of chronic renal support, providing the necessary and indispensable background to the work of RDRTF.
- There are some **THREATS** for the RDRTF:
- The headquarters are localized in only one single center (Renal division of UH Ghent requiring complex organizational activities, necessitating full-time involvement of one medical coordinator and at least one secretarial assistant.
- In addition, keeping the program and volunteers up-to-date is cumbersome because of unpredictability of interventions
- escalating number of unsafe and war struck areas on a global level
- growing number of regions where dialysis is provided for the happy few, but not for all, creating ethical problems when bringing in acute dialysis opportunities during a short lived window.

UREMIC TOXINS: GUT-KIDNEY INTERACTION


R Vanholder
University Hospital, Gent,
Belgium

SUMMARY


- ➔ **CKD: a devastating disease**
- ➔ **Role of the intestine in CKD morbidity**
 - ➔ Loss of intestinal integrity
 - ➔ Pro-inflammatory effect
 - ➔ Generation of uremic toxins
- ➔ **Potential impact of probiotics**
 - ➔ Anti-inflammatory effect
 - ➔ Decrease uremic toxin concentration

CKD IS A DEVASTATING DISEASE

CHRONIC KIDNEY DISEASE: THE MORTALITY CHALLENGE




MORTALITY DIALYSIS HIGHER THAN FOR CANCER




Based on US data

IN CKD VIRTUALLY ALL BIOCHEMICAL AND ORGANS SYSTEMS ARE AFFECTED




YEARLY AGGREGATED COST CKD ≥ CA/DM

YEARLY COST –
BILLION €



Vanholder et al, unpublished

MORBIDITY AND MORTALITY ARE DUE TO CKD, NOT TO COMORBIDITIES



Fai Xan et al, JASN, 30, 1991-1999, 2019

ROLE OF THE INTESTINE IN UREMIC MORBIDITY AND MORTALITY

CKD DISTURBS INTEGRITY OF THE INTESTINAL EPITHELIUM

Nephrol Dial Transplant (2012) 27: 2686–2693
doi: 10.1093/ndt/gfr624
Advance Access publication 29 November 2011

Original Articles

NDT
Nephrology Dialysis Transplantation


Disintegration of colonic epithelial tight junction in uremia: a likely cause of CKD-associated inflammation

Nosratola D. Vaziri, Jun Yuan, Ardeshir Rahimi, Zhenmin Ni, Hyder Said and
Veendamali S. Subramanian

Division of Nephrology and Hypertension, Department of Medicine, University of California, Irvine, CA, USA

Correspondence and offprint requests to: Nosratola D. Vaziri; E-mail: ndvaziri@uci.edu

CKD DISTURBS INTEGRITY OF THE INTESTINAL EPITHELIUM



UREA DISRUPTS INTESTINAL WALL PROTECTIVE BARRIER

Original Report: Laboratory Investigation

Nephrology
American Journal of

Am J Nephrol 2013;37:1–6
DOI: [10.1159/000345969](https://doi.org/10.1159/000345969)

Received: October 22, 2012
Accepted: November 20, 2012
Published online: December 19, 2012

Role of Urea in Intestinal Barrier Dysfunction and Disruption of Epithelial Tight Junction in Chronic Kidney Disease

Nosratola D. Vaziri^a Jun Yuan^a Keith Norris^b

^aDivision of Nephrology and Hypertension, University of California, Irvine, Calif., and ^bDepartment of Internal Medicine, Charles Drew University, Los Angeles, Calif., USA

UREA DISRUPTS INTESTINAL WALL PROTECTIVE BARRIER




Figure 1
Bar graphs depicting the TER (transepithelial electrical resistance) in intestinal epithelial T84 cell monolayers incubated for 24 h in regular media and those incubated in media containing 42 or 72 mg/dl urea. *** $p < 0.001$.

CKD IS ASSOCIATED WITH TRANSLOCATION OF GUT BACTERIAL DNA – GUT GENUS DETECTED IN BLOOD (% OF TOTAL GUT GENUS)

NEPHROLOGY



Nephrology 17 (2012) 733–738

Original Article

Gut bacterial translocation is associated with microinflammation in end-stage renal disease patients

FEIQIAN WANG,¹ HONGLI JIANG,¹ KEHUI SHI,¹ YI REN,¹ PAN ZHANG¹ and SHAOLI CHENG²

¹Dialysis Department of Nephrology Center, First Affiliated Hospital of Medicine School, Xi'an Jiaotong University, ²Morphological Experiment Centre, Medicine School of Xi'an Jiaotong University, Xi'an, Shaanxi, China

KEY WORDS:

bacteria translocation, end-stage renal disease, gut, microbiome dysbiosis, microinflammation.

Correspondence:

Dr Hongli Jiang, Dialysis Center of First Affiliated Hospital of Medicine School, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China. Email: j92106@sina.com

Accepted for publication 16 July 2012.
Accepted manuscript online 23 July 2012.

doi:10.1111/j.1440-1797.2012.01647.x

SUMMARY AT A GLANCE

Wang *et al.* evaluated the bacterial translocation in the intestinal tract in non-dialysed ESRD patients and its contribution to microinflammation in the patient population.

ABSTRACT

Aim: To investigate whether gut bacteria translocation occurs in end-stage renal disease patients and contributes to microinflammation in end-stage renal disease (ESRD).

Methods: The subjects were divided into two groups: nondialysed ESRD patients ($n = 30$) and healthy controls ($n = 10$). Blood samples from all participants were subjected to bacterial 16S ribosomal DNA amplification and DNA pyrosequencing to determine the presence of bacteria, and the alteration of gut microbiomes were examined with the same methods. High-sensitive C-reactive protein and interleukin-6 were detected. Plasma D-lactate was tested for gut permeability.


Results: Bacterial DNAs were detected in the blood of 20% (6/30) of the ESRD patients. All the observed genera in blood (*Klebsiella* spp, *Proteus* spp, *Escherichia* spp, *Enterobacter* spp, and *Pseudomonas* spp) were overgrown in the guts of the ESRD patients. Plasma D-lactate, High-sensitive C-reactive protein, and interleukin-6 levels were significantly higher in patients with bacterial DNA than those without. The control group showed the same results as that of patients without bacterial DNA.

Conclusion: Bacterial translocation occurs in ESRD patients and is associated with microinflammation in end stage renal disease.

CKD IS ASSOCIATED WITH TRANSLOCATION OF GUT BACTERIAL DNA – GUT GENUS DETECTED IN BLOOD (% OF TOTAL GUT GENUS)

	Controls (n=10)	ESRD (n=30)	P
<i>Klebsiella</i> spp	0.60	1.93	0.037
<i>Proteus</i> spp	0.12	10.61	0.011
<i>Escherichia</i> spp	0.42	4.33	0.045
<i>Enterobacter</i> spp	0	0.42	0.001
<i>Pseudomonas</i> spp	0.04	0.23	0.014

ROLE INTESTINE IN GENERATION CRESOLS



BRIEF REVIEW


www.jasn.org

The Uremic Toxicity of Indoxyl Sulfate and p-Cresyl Sulfate: A Systematic Review

Raymond Vanholder, Eva Schepers, Anneleen Pletinck, Evi V. Nagler, and Griet Glorieux

Nephrology Section, Ghent University Hospital, Ghent, Belgium

INDOXYLSULFATE AND P-CRESYLSULFATE HAVE BEEN LINKED TO A MYRIAD OF TOXIC EFFECTS:



Vanholder et al, JASN, 25, 1897-1907, 2014

TMAO ENHANCES ATHEROGENESIS


ARTICLE

doi:10.1038/nature09922

Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease

Zeneng Wang^{1,2}, Elizabeth Klipfell^{1,2}, Brian J. Bennett³, Robert Koeth¹, Bruce S. Levison^{1,2}, Brandon DuGar¹, Ariel E. Feldstein^{1,2}, Earl B. Britt^{1,2}, Xiaoming Fu^{1,2}, Yoon-Mi Chung^{1,2}, Yuping Wu⁴, Phil Schauer⁵, Jonathan D. Smith^{1,6}, Hooman Allayee⁷, W. H. Wilson Tang^{1,2,6}, Joseph A. DiDonato^{1,2}, Aldons J. Lusis³ & Stanley L. Hazen^{1,2,6}

TMAO ENHANCES ATHEROGENESIS



Role of intestinal microbiota: effect precursors TMAO neutralized by antibiotics



International Journal of
Molecular Sciences




Article

Isolation and Quantification of Uremic Toxin Precursor-Generating Gut Bacteria in Chronic Kidney Disease Patients

Tessa Gryp ^{1,2,3,*} , Geert R.B. Huys ³ , Marie Joossens ³ , Wim Van Biesen ¹,
Griet Glorieux ^{1,†}  and Mario Vaneechoutte ^{2,†}

INTESTINAL MICROBIOTA CHANGE IN CKD




Gryp et al, Int J Mol Sci, 21, 1986, 2020

Gut microbiota dynamics and uraemic toxins: one size does not fit all

Marie Joossens,^{1,2} Karoline Faust,¹
Tessa Gryp,^{1,3,4} Anh Thi Loan Nguyen,⁵
Jun Wang,^{1,2,6} Sunny Eloit,³ Eva Schepers,³
Annemieke Dhondt,³ Anneleen Pletinck,³
Sara Vieira-Silva,^{1,2} Gwen Falony,^{1,2}
Mario Vaneechoutte,⁴ Raymond Vanholder,³
Wim Van Biesen,³ Geert Roger Bertrand Huys,^{1,2}
Jeroen Raes,^{1,2} Griet Glorieux³

TOXINS STEM FROM DIFFERENT MICROBIOTA



NO INCREASE IN INTESTINAL GENERATION IN CKD

www.kidney-international.org

clinical investigation


Gut microbiota generation of protein-bound uremic toxins and related metabolites is not altered at different stages of chronic kidney disease

OPEN

Tessa Gryp^{1,2,3}, Kim De Paepe⁴, Raymond Vanholder¹, Frederiek-Maarten Kerckhof⁴, Wim Van Biesen¹, Tom Van de Wiele⁴, Francis Verbeke¹, Marijn Speeckaert¹, Marie Joossens³, Marie Madeleine Couttenye⁵, Mario Vaneechoutte² and Griet Glorieux¹


Gryp et al, KI, 97, 1230-1242, 2020

NO INCREASE IN INTESTINAL GENERATION IN CKD




Gryp et al, KI, 97, 1230-1242, 2020

NO INCREASE IN INTESTINAL GENERATION IN CKD



Gryp et al, KI, 97, 1230-1242, 2020

NO INCREASE IN INTESTINAL GENERATION IN CKD



Gryp et al, KI, 97, 1230-1242, 2020

THERAPEUTIC OPTIONS

THERAPEUTIC OPTIONS

- ➔ **Diet**
 - ➔ **Cave malnutrition**
- ➔ **Prebiotics**
 - ➔ **Non-digestible compounds beneficially modifying composition and/or function of intestinal flora**
- ➔ **Probiotics**
 - ➔ **Bacteria administered as food components or supplements providing specific benefits themselves**
- ➔ **Synbiotics**
 - ➔ **Prebiotics + probiotics**
- ➔ **Sorbents**

THERAPEUTIC OPTIONS

- **Diet**
 - **Cave malnutrition**
- **Prebiotics**
 - **Non-digestible compounds beneficially modifying composition and/or function of intestinal flora**
- **Probiotics**
 - **Bacteria administered as food components or supplements providing specific benefits themselves**
- **Synbiotics**
 - **Prebiotics + probiotics**
- **Sorbents**

INFLAMMATION

ANTI-INFLAMMATORY EFFECT PROBIOTICS: DECREASE CRP – META-ANALYSIS



nutrients



Review


Impact of Probiotic Administration on Serum C-Reactive Protein Concentrations: Systematic Review and Meta-Analysis of Randomized Control Trials

Mohsen Mazidi ^{1,2}, Peyman Rezaie ³, Gordon A. Ferns ⁴ and Hassan Vatanparast ^{5,*}

ANTI-INFLAMMATORY EFFECT PROBIOTICS: DECREASE CRP – META-ANALYSIS

Study name

Std diff in means and 95% CI



SALT INTAKE, INFLAMMATION AND HYPERTENSION


ARTICLE

doi:10.1038/nature24628

Salt-responsive gut commensal modulates T_H17 axis and disease



Nicola Wilck^{1,2,3,4,5}, Mariana G. Matus^{6,7}, Sean M. Kearney⁶, Scott W. Olesen⁶, Kristoffer Forslund⁸, Hendrik Bartolomaeus^{1,2,3,4}, Stefanie Haase⁹, Anja Mähler^{1,5}, András Balogh^{1,2,3,4,5}, Lajos Markó^{1,2,3,4,5}, Olga Vvedenskaya^{3,10,11}, Friedrich H. Kleiner¹, Dmitry Tsvetkov^{1,2}, Lars Klug^{1,5}, Paul I. Costea⁸, Shinichi Sunagawa^{8,12}, Lisa Maier¹³, Natalia Rakova^{1,9}, Valentin Schatz¹⁴, Patrick Neubert¹⁴, Christian Frätzer¹⁵, Alexander Krannich⁵, Maik Gollasch^{1,2,3}, Diana A. Grohme¹⁶, Beatriz F. Côrte-Real¹⁷, Roman G. Gerlach¹⁸, Marijana Basic¹⁹, Athanasios Typas¹³, Chuan Wu²⁰, Jens M. Titze²¹, Jonathan Jantsch¹⁴, Michael Boschmann^{1,5}, Ralf Dechend^{1,2,5}, Markus Kleiweietfeld^{16,17,22}, Stefan Kempa^{3,5,10}, Peer Bork^{3,8,23,24}, Ralf A. Linker^{9§}, Eric J. Alm^{6§} & Dominik N. Müller^{1,2,3,4,5§}

SALT INTAKE, INFLAMMATION AND HYPERTENSION






NSD: normal salt diet
HSD: high salt diet
L. murinus:
Lactobacillus murinus

SALT INTAKE, INFLAMMATION AND HYPERTENSION



NSD: normal salt diet
HSD: high salt diet
L. murinus:
Lactobacillus murinus

SALT INTAKE, INFLAMMATION AND HYPERTENSION



NSD: normal salt diet
 HSD: high salt diet
L. murinus:
 Lactobacillus murinus

UREMIC TOXIN CONCENTRATION


DECREASE UREMIC TOXINS WITH SYNBIOTICS: RCT

Article

Synbiotics Easing Renal Failure by Improving Gut Microbiology (SYNERGY): A Randomized Trial

Megan Rossi,^{,†‡} David W. Johnson,^{*,†‡} Mark Morrison,^{†§} Elaine M. Pascoe,^{*} Jeff S. Coombes,^{||} Josephine M. Forbes,^{*,†¶}
Cheuk-Chun Szeto,^{**} Brett C. McWhinney,^{††} Jacobus P.J. Ungerer,^{††} and Katrina L. Campbell^{*,†‡}*


DECREASE UREMIC TOXINS WITH SYNBIOTICS: RCT



^a Treatment effect (95% CI) derived from regression modelling accounting for period effect
* p=0.03
** p=0.001

Figure 3. Treatment effect of synbiotics on serum uremic toxins in all completing patients (n=31) and patients who were antibiotic free (n=21). ^aTreatment effect (95% confidence interval) derived from regression modeling accounting for period effect. *P=0.03; **P=0.001.


DECREASE UREMIC TOXINS WITH SYNBIOTICS: RCT



^a Treatment effect (95% CI) derived from regression modelling accounting for period effect
 * $p=0.03$
 ** $p=0.001$

Figure 3. Treatment effect of synbiotics on serum uremic toxins in all completing patients ($n=31$) and patients who were antibiotic free ($n=21$). ^aTreatment effect (95% confidence interval) derived from regression modeling accounting for period effect. * $P=0.03$; ** $P=0.001$.

DECREASE UREMIC TOXINS WITH SYNBIOTICS: RCT



^a Treatment effect (95% CI) derived from regression modelling accounting for period effect
 * p=0.03
 ** p=0.001

Figure 3. Treatment effect of synbiotics on serum uremic toxins in all completing patients (n=31) and patients who were antibiotic free (n=21). ^aTreatment effect (95% confidence interval) derived from regression modeling accounting for period effect. *P=0.03; **P=0.001.

PROBIOTICS DECREASE UREMIC TOXINS

Author	Reference	Toxin
Garcia-Arroyo et al	Plos One, 13, e0202901, 2018	Uric acid
Dunn et al	Int Dairy J, 8, 545-553, 1998	DMA, NDMA
Takayama et al	AJKD, 41 (Suppl 1), S142-S145, 2003	Indoxyl sulfate
Guida at al	Nutr Metab Cardiovasc Dis, 24, 1043-1049, 2014	P-cresol
Simeoni et al	Eur J Nutr, doi: 10.1007/s00394-018-1785-z	β 2-M, PTH
Thongprayoon et al	Digest Dis Sci, doi: 10.1007/s10620-018-5243-9	PBUT
Firouzi et al	Nutrition, 51-52, 104-113, 2018	Urea
Saggi et al	Int J Probiot Prebiot, 12, 43-54, 2017	Urea
Deghani et al	Iran J kidney Dis, 10, 351-357, 2016	Urea
Ranganathan et al	Scientif World J, 5, 652-666, 2005	Urea

DMA: dimethylarginine, NDMA: nitrosodimethylarginine, β 2-M: β 2-microglobulin, PTH: parathyroid hormone; PBUT: protein bound uremic toxins

UREA IS NOT INERT

Nephrol Dial Transplant (2018) 33: 4-12
doi: 10.1093/ndt/gfx039
Advance Access publication 12 April 2017



Full Reviews

Urea and chronic kidney disease: the comeback of the century? (in uraemia research)

Raymond Vanholder¹, Tessa Gryp² and Griet Glorieux²

¹Nephrology Section, Department of Internal Medicine, Ghent University Hospital, Ghent, Belgium and ²Laboratory for Bacteriology Research, Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium

Correspondence and offprint requests to: Raymond Vanholder; E-mail: Raymond.vanholder@ugent.be

UREA INDUCES INSULIN RESISTANCE

JCI The Journal of Clinical Investigation

Amendment history:

- [Addendum](#) (October 2014)
- [Erratum](#) (March 2010)

Urea-induced ROS generation causes insulin resistance in mice with chronic renal failure

Maria D'Apolito, ... , Michael Brownlee, Ida Giardino

J Clin Invest. 2010;120(1):203-213. <https://doi.org/10.1172/JCI37672>.

UREA INDUCES INSULIN RESISTANCE




Figure 3
Urea causes decreased insulin sensitivity in differentiated 3T3L1 adipocytes. (A) Effect of urea on insulin-stimulated glucose uptake in differentiated 3T3L1 cells.

UREA INDUCES INSULIN RESISTANCE




Figure 3
 Urea causes decreased insulin sensitivity in differentiated 3T3L1 adipocytes. (A) Effect of urea on insulin-stimulated glucose uptake in differentiated 3T3L1 cells.

UREA IS RELATED TO THE DEVELOPMENT OF DIABETES MELLITUS

www.kidney-international.org

clinical investigation


Higher blood urea nitrogen is associated with increased risk of incident diabetes mellitus



OPEN

Yan Xie¹, Benjamin Bowe¹, Tingting Li^{1,2}, Hong Xian^{1,3}, Yan Yan^{1,4} and Ziyad Al-Aly^{1,2,5,6}

UREA IS RELATED TO THE DEVELOPMENT OF DIABETES MELLITUS



PROGRESSION CKD

PROBIOTICS REFRAIN PROGRESSION OF CKD

© 2014 EDIZIONI MINERVA MEDICA

The online version of this article is located at <http://www.minervamedica.it>

Minerva Urologica e Nefrologica 2016 April;68(2):222-6

ORIGINAL ARTICLE NEPHROLOGY

Influence of prebiotic and probiotic supplementation on the progression of chronic kidney disease

Malleshappa PAVAN*



CONCLUSIONS

CONCLUSIONS

- ➔ **CKD is a devastating disease**

CONCLUSIONS

- ➔ **CKD is a devastating disease**
- ➔ **The gut plays a patho-physiologic role by inducing inflammation and generating uremic toxins**

CONCLUSIONS

- ➔ **CKD is a devastating disease**
- ➔ **The gut plays a patho-physiologic role by inducing inflammation and generating uremic toxins**
- ➔ **Probiotics may alter this chain of events by:**
 - ➔ An anti-inflammatory effect
 - ➔ Reducing uremic toxins

CONCLUSIONS

- ➔ **CKD is a devastating disease**
- ➔ **The gut plays a patho-physiologic role by inducing inflammation and generating uremic toxins**
- ➔ **Probiotics may alter this chain of events by:**
 - ➔ An anti-inflammatory effect
 - ➔ Reducing uremic toxins
- ➔ **Evidence on the impact of probiotics could be strengthened**